Shares of Iovance Biotherapeutics surged following the announcement of accelerated approval from the U.S. Food and Drug Administration for its groundbreaking metastatic melanoma treatment. Significant Stock Surge With a remarkable 41% increase on Tuesday, Iovance's stock reached $12.86, marking its most substantial growth since June 3, 2016, when it saw a surge of 43%, as … [Read more...] about Iovance Biotherapeutics FDA Approval
Footer
